Indivior PLC (INDV) Receives Buy Rating from Numis Securities Ltd
Numis Securities Ltd reaffirmed their buy rating on shares of Indivior PLC (LON:INDV) in a research note issued to investors on Friday morning. The brokerage currently has a GBX 470 ($6.08) price objective on the specialty pharmaceutical company’s stock.
INDV has been the topic of a number of other reports. Jefferies Group LLC lifted their price target on Indivior PLC from GBX 490 ($6.34) to GBX 540 ($6.98) and gave the company a buy rating in a research note on Friday, August 11th. Royal Bank Of Canada restated an outperform rating and issued a GBX 470 ($6.08) price target on shares of Indivior PLC in a research note on Thursday, August 3rd. Finally, Stifel Nicolaus restated a buy rating and issued a GBX 500 ($6.47) price target on shares of Indivior PLC in a research note on Thursday, May 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Indivior PLC currently has a consensus rating of Buy and an average price target of GBX 452.50 ($5.85).
Shares of Indivior PLC (LON INDV) traded down 35.77% on Friday, hitting GBX 267.60. The stock had a trading volume of 10,316,848 shares. The company’s market cap is GBX 1.93 billion. The firm’s 50-day moving average is GBX 375.36 and its 200-day moving average is GBX 340.95. Indivior PLC has a one year low of GBX 246.50 and a one year high of GBX 421.50.
COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/02/indivior-plc-indv-receives-buy-rating-from-numis-securities-ltd.html.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Stock Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related stocks with our FREE daily email newsletter.